HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in Am J Health-Syst Pharm Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hahn, K. K. Articles by Kolesar, J. M. Search for Related Content PubMed PubMed Citation Articles by Hahn, K. K. Articles by Kolesar, J. M.

KRISTINE K. HAHN, PHARM.D., is Clinical Instructor, University of Wisconsin Comprehensive Cancer Center (UWCCC), Madison. JAMES J. WOLFF is a Pharm.D. degree candidate, School of Pharmacy, University of Wisconsin (UW), Madison. JILL M. KOLESAR, PHARM.D., is Director, Analytical Instrumentation Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics, UWCCC, and Associate Professor of Pharmacy, School of Pharmacy, UW.

Address correspondence to Dr. Kolesar at the School of Pharmacy, University of Wisconsin, 777 Highland Avenue, Madison, WI 53705 (jmkolesar{at}pharmacy.wisc.edu).

Purpose. Irinotecan metabolism, irinotecan pharmacogenetic research, and the role of genetic testing before administration of the drug are reviewed. Summary. Irinotecan is approved worldwide for the treatment of metastatic colorectal cancer but causes dose-limiting neutropenia and diarrhea. When severe, these can lead to dehydration, infection, patient discomfort, additional medication requirements, hospitalization, and death. The identification of predictive markers in irinotecan therapy has been a significant goal of pharmacogenetic research. The labeling of irinotecan was recently changed and now includes a warning of greater neutropenia risk in patients with reduced activity in the drug-metabolizing enzyme uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). A known marker of reduced UGT1A1 activity is the genetic variant UGT1A1*28. Numerous studies have demonstrated the effects of genetic factors, especially UGT1A1*28, that contribute to interpatient variability in irinotecan pharmacokinetics and toxicity. Irinotecan’s new labeling recommends that clinicians consider reducing the dosage of irinotecan in patients homozygous for UGT1A1*28. Conclusion. At least part of the interpatient variability of irinotecan toxicity can be explained by the UGT1A1*28 polymorphism. Patients who are homozygous for the UGT1A1*28 allele have an increased risk of developing severe neutropenia when receiving irinotecan, especially the 300–350- mg/m2 regimen. A molecular assay is now available to identify the at-risk subgroup and should be used by health care professionals to help guide irinotecan-treatment decisions. Index terms: Antineoplastic agents; Colorectal neoplasms; Dosage; Genetics; Irinotecan; Labeling; Metabolism; Neoplasm metastasis; Pharmacogenetics; Pharmacokinetics; Polymorphism; Tests; Toxicity

 

Related articles in Am J Health-Syst Pharm:

Searching for the Holy Grail of oncology

Gerald M. Higa
Am J Health-Syst Pharm 2006 63: 2260-2262. [Full Text]  

This article has been cited by other articles:

				F. Meyer-Losic, C. Nicolazzi, J. Quinonero, F. Ribes, M. Michel, V. Dubois, C. de Coupade, M. Boukaissi, A.-S. Chene, I. Tranchant, et al. DTS-108, A Novel Peptidic Prodrug of SN38: In vivo Efficacy and Toxicokinetic Studies Clin. Cancer Res., April 1, 2008; 14(7): 2145 - 2153. [Abstract] [Full Text] [PDF]

				G. M. Higa Searching for the Holy Grail of oncology Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2260 - 2262. [Full Text] [PDF]